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Rheumatoid arthritis: diagnosis and treatment 
with a particular emphasis on South Sudan
Charles Radisa d.o.
Rheumatoid arthritis (RA) is a 
chronic, systemic, autoimmune 
inflammatory disorder targeting 
diarthrodial synovial lined 
joints, usually in a symmetric 
distribution. The lungs, 
pericardium of  the heart, skin, 
and eyes may be affected in up 
to twenty percent of  patients. 
If  uncontrolled, RA leads to 
joint destruction, disability, 
and a significantly shortened 
life span.
In developing countries 
where medical resources are 
limited, recognition and aggressive management of  patients 
with rheumatoid arthritis may lag behind the treatment 
of  infectious diseases associated with high mortality such 
as malaria, tuberculosis, HIV, and cholera. However, 
the burden of  progressive 
pain and disability from the 
arthritis and its effect on the 
individual and family unit is 
considerable.  Since specialists 
in rheumatologic care are 
rare in developing countries, 
the focus of  this review is to 
improve the ability of  general 
clinicians to diagnose early 
rheumatoid arthritis, and 
to initiate treatment within 
the limitations of  available 
therapeutic options.  A typical 
case is presented to illustrate 
key diagnostic features of  the 
disease and management decisions.
A 23 year old female presented to clinic with a three 
months’ history of  pain, stiffness, and swelling of  the 
proximal interphalangeal (PIP) joints, wrists, and knees. 
The symptoms began six months after the birth of  her 
third child. She was breastfeeding 
and having difficulty lifting her 
baby, washing clothes, and cooking. 
Morning stiffness is present for 
2 hours and is accompanied by 
considerable fatigue. She denied 
a recent cough, change in bowel 
habits, weight loss, or fever. A 
maternal grandmother became 
crippled at an early age and was 
bed-bound for the last four years 
of  her life.
On examination, she walks with 
a slight limp. There is swelling and 
subtle erythema appreciated in the 
second, third, fourth, and fifth MCP joints of  both hands, 
and diffuse fusiform swelling in the PIP joints along 
with tenderness and swelling in both wrists and knees. 
At the right elbow is a freely movable nodule measuring 
approximately one centimeter. 
Her physical exam is otherwise 
unremarkable.
Epidemiology of rheumatoid 
arthritis
RA affects women more frequently 
than men by a ratio of  3:1. 
Although patients may present in 
childhood or at an advanced age, 
the peak incidence is in the child-
bearing years. The disease has a 
world-wide prevalence of  0.8% but 
there is controversy regarding the 
incidence of  RA in Africa. Some 
studies suggest that it occurs in 
only 0.1% of  rural Africans, but rigorous epidemiologic 
studies have not been performed in most regions of  
Africa. A review of  406 cases at the Mulago Hospital in 
Uganda in 1980 suggested that RA was not infrequent and 
it was often severe [1]. A link to urban living may exist, as 
a study in Soweto, South Africa, showed a prevalence of  
RA among blacks similar to white Europeans [2].  
The triggering event for rheumatoid arthritis is 
unknown. Many patients with RA have other family 
members affected by the disease, suggesting a genetic 
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Figure 1. Early RA affecting the MCP PIP joints      
(credit C. Radis)
Figure 2. Progressive RA deformities (credit C. Radis)
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predisposition. HLA testing has linked an increased 
risk for developing RA to the HLA-DR4 region, with 
the highest risk associated with the HLA-DR01 allele. 
Since a minority of  patients who are HLA-DR4 positive 
develop the disease, it is postulated that an additional 
environmental factor(s) may trigger the disease. Known 
risk factors currently include smoking with a relative risk 
reported as high as 8.8 [3] in a genetically predisposed 
individual, and chronic periodontal disease [4]. 
Extra-articular manifestations of rheumatoid 
arthritis 
Rheumatoid arthritis is a systemic disease in that although 
synovial lined joints are a major target (see Figures 1 and 
2), other organ systems are frequently affected. In general, 
patients with extra-articular disease have more severe and 
long-standing RA, but in some patients extra-articular 
disease may occur early and may be organ threatening. 
Sjogren’s syndrome, with manifestations of  dry eyes and 
dry mouth may affect up to 50% of  RA patients over 
a lifetime. Patients may also present with episcleritis or 
scleritis (including corneal melt). Diagnosing RA eye 
involvement and initiating proper treatment may require 
ophthalmologic consultation. 
Rheumatoid nodules affect up to 20% of  RA patients. 
Nodules are most commonly palpable along the ulnar 
aspect of  the elbow and forearm but may also occur at 
the Achilles tendons or in the hands. They are usually 
asymptomatic and may recur if  surgically excised. 
Rheumatoid nodules may occasionally involve the lung 
parenchyma (see Figure 3). Differentiating rheumatoid 
nodules in the lung from malignancy or infection may 
require biopsy. The lung pleura and the pericardium may 
also be targeted by RA. Pleural effusions and pericardial 
effusions are not uncommon and may require thoracentesis 
or pericardiocentesis to differentiate from other causes of  
pleuropericarditis. Interstitial lung disease attributable to 
RA is usually mild and may be asymptomatic, but aggressive 
immunotherapy may be necessary in patients with 
progressive disease. Vasculitis secondary to RA is a feared 
complication of  the disease. Small vessel leukocytoclastic 
vasculitis involving the skin is often present (see Figure 4). 
RA vasculitis may trigger mononeuritis multiplex, sensory 
neuropathy, and the gastrointestinal tract with bowel 
ischaemia and perforation. 
diagnosis
Despite improvements in laboratory assessment, 
rheumatoid arthritis continues to be a clinical diagnosis. 
The 2010 American College of  Rheumatology (ACR)/
European League Against Rheumatism (EULAR) criteria 
for the diagnosis of  rheumatoid is summarized in Box 1. 
Although a 
clinical diagnosis 
of  rheumatoid 
arthritis may 
occasionally be 
made in patients 
who have a 
EULAR score less 
than 6, the clinical 
criteria emphasize 
well known aspects 
of  typical RA 
patients: small and 
large joint synovitis 




polyarthritis seen in 
rubella, parvovirus, hepatitis B, and C, and Chikungunya 
from RA is usually possible by the presence of  rash, fever, 
or the presence of  myalgias. In addition, viral polyarthritis 
usually reaches a peak in several days and gradually resolves 
while patients with early RA usually add joints over time 
with increasing stiffness and swelling. 
Other forms of  chronic inflammatory arthritis 
must be differentiated from RA. Patients with psoriatic 
arthritis may present with symmetric small and large joint 
synovitis but careful skin exam usually demonstrates 
patches of  psoriasis, nail pitting or onycholysis. Patients 
with systemic lupus erythematosus (SLE) may also 
present with polyarthritis but often have oral or nasal 
ulcers, photosensitive rash, pleurisy, or pericarditis. HIV 
Figure 3. RA rheumatoid nodules  
Box 1. Eular Classification criteria for RA 
(score-based algorithm: add score of  categories A–D; a score of
 ≥6/10 is needed for classification of  a patient as having definite
 RA)
A. Joint involvement 
1 large joint:  0
2-10 large joints: 1
1-3 small joints (with or without involvement of  large joints): 2
4-10 small joints (with or without involvement of  large joints): 3
>10 joints (at least 1 small joint): 5
B. Serology (at least 1 test result is needed for classification)
Negative rheumatoid factor (RF)  and negative ACPA: 0
Low-positive RF or low-positive ACPA: 2
High-positive RF or high-positive ACPA: 3
C. Acute-phase reactants (at least 1 test result is needed for
 classification)
Normal C-reactive protein (CRP) and normal ESR: 0
Abnormal CRP or abnormal ESR: 1
D. Duration of  symptoms
<6 weeks:  0
≥6 weeks:  1
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may trigger inflammatory arthritis. HIV 
patients may have significant cervical 
lymphadenopathy, splenomegaly  and 
a wasting syndrome. If  there are 
risk factors for HIV (multiple sexual 
partners or IV drug use) in a patient 
with polyarthritis, testing for HIV is 
recommended. 
Rheumatoid factors are antibodies 
directed against the Fc portion of  native 
IgG. In early RA, only 50% of  patients 
have a positive rheumatoid factor, while 
in late disease, about 80% of  patients 
have detectable rheumatoid factors. 
Rheumatoid factors are often present 
in other disorders including sub-acute 
bacterial endocarditis, tuberculosis, 
sarcoidosis, chronic hepatitis B and C, 
and HIV disease.  Thus, rheumatoid 
factors have relatively low sensitivity and 
specificity for the diagnosis of  RA.  High titre rheumatoid 
factors however, are much more frequently seen in RA 
than in other disorders and may predict severe disease. 
A newer laboratory test which measure antibodies 
against cyclic citrullinated peptide (ACPA) has much 
higher specificity in the diagnosis of  RA (about 96% in 
Caucasians) and similar sensitivity (80%) compared to 
rheumatoid factor. A recently published study of  black 
South Africans with early RA may point towards differences 
in ACPA specificity between African and European 
patients. In this study, ACPA was no more specific for 
the diagnosis of  RA than traditional rheumatoid factors. 
Nearly a third of  systemic lupus patients tested positive 
for ACPA. Based on this study, the authors suggest testing 
for ACPA antibodies only if  a patient is RF negative [5]. 
Treatment of rheumatoid arthritis
Timely and aggressive treatment of  early rheumatoid 
arthritis with disease modifying medications (DMARDS) 
may prevent or slow the progression of  joint damage. 
Although anti-inflammatories (NSAIDS) such as 
ibuprofen, naproxyn sodium, diclofenac, and others, may 
help with pain and stiffness, they do not prevent joint 
damage. NSAIDS are frequently prescribed for joint pain 
and stiffness in rheumatoid arthritis, but clinicians need 
to be vigilant with clinical and laboratory monitoring to 
ensure these medications do not trigger renal or hepatic 
damage. Patients with congestive heart failure, diabetes 
mellitus, uncontrolled hypertension, or advanced age 
may be at particular risk for renal insufficiency. Heavy 
alcohol use and cigarette smoking increase the risk of  
peptic ulcer disease or NSAID induced 
gastritis. Regular monitoring of  serum 
creatinine and complete blood counts 
are recommended in patients at risk for 
NSAID side-effects. 
Judicious use of  corticosteroid 
injections and/or oral prednisone or 
methylprednisolone may reduce pain and 
improve function. Oral corticosteroids 
are often dramatically effective short-
term but cumulatively have a host 
of  side-effects including weight gain, 
fluid retention, glaucoma, diabetes 
mellitus, adrenal insufficiency, reduced 
bone density, and recurrent infections. 
Because these medications are relatively 
inexpensive and widely available, 
clinicians may find that benefits versus 
risks favour their use. At doses of  5 mg 
prednisone or 4 mg methylprednisolone 
daily, risks may be minimalized. Above these daily doses, 
long-term side-effects are inevitable and sometimes 
catastrophic. There is conflicting evidence as to whether 
low-dose oral corticosteroids prevent joint damage [6].
Most, if  not all, RA patients should be prescribed a 
disease modifying medication. DMARDS do not cure RA, 
but when used singly or in combination, they may slow 
down or prevent joint destruction and offer patients the 
greatest hope of  living a more comfortable and productive 
life. Current DMARDS include hydroxychloroquine, 
sulfasalazine, leflunomide, methotrexate, and an expanding 
family of  medications termed biologic response modifiers. 
Biologic response modifiers block the function of  key 
drivers of  the immune system in rheumatoid arthritis. 
Infliximab, etanercept, and adalimumab are antibodies 
to tumor necrosis factor (TNF), while tocilizumab is an 
antibody directed against the receptor for the cytokine 
interleukin-6. An antibody against the CD20 antigen 
present on B cells is the target of  Rituximab. This B 
cell depleting drug leads to decreased B cell help in the 
complex immune response which perpetuates rheumatoid 
arthritis.
The drawbacks to the routine use of  biologic response 
modifiers in developing countries are considerable. The 
average cost for these medications is more than $20,000 
U.S. dollars yearly. The re-emergence of  latent TB or the 
new development of  TB and fungal diseases may be seen in 
patients prescribed TNF blockers, particularly in countries 
where the incidence of  TB is high. Nevertheless, biologic 
response modifiers play a critical role in controlling RA 
in patients with severe disease unresponsive to traditional 
Figure 4. RA small vessell vasculitis
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DMARDs and in future years, these medications should 
be available to clinicians in South Sudan. 
At a recent lecture at the Juba Teaching Hospital, this 
writer was made aware that DMARDS are not generally 
available in South Sudan. RA patients and their doctors 
must obtain these medications from outside countries. 
Thus, even with increasing recognition of  the crippling 
effects of  RA, this limits therapeutic options for patients. 
The traditional DMARDS such as Hydroxychloroquine, 
sulfasalazine, methotrexate, and leflunomide are 
the cornerstone of  effective treatment in most RA 
patients.  Hydroxychloroquine and sulfasalazine are 
inexpensive, generally well tolerated, and do not require 
extensive laboratory monitoring. Because of  the risk 
of  retinal toxicity with hydroxychloroquine, a baseline 
eye check is recommended by the American College of  
Ophthalmology with a second eye evaluation at five years 
and then yearly thereafter for patients who remain on the 
drug [7]. The effective dose of  hydroxychloroquine is 400 
mg/day and the drug may take 2-4 months to reach full 
effectiveness. Patients taking Hydroxychloroquine should 
not exceed a total daily dose of  greater than 6.5 mg/kg/
day. Sulfasalazine is another DMARD which is relatively 
inexpensive, well tolerated, and effective in many patients 
with RA. The usual dose is 2-3 grams daily in divided 
doses. A baseline Complete Blood Count (CBC) is 
recommended, with a repeat CBC at 3-6 month intervals 
due to the risk of  leucopenia or thrombocytopaenia.
Methotrexate  is considered a cornerstone of  therapy 
in most RA patients. It should be prescribed in early 
disease with monitoring of  liver enzymes and complete 
blood counts. Patients with pre-existing liver disease or 
renal insufficiency should not be prescribed methotrexate. 
Baseline and monthly laboratory testing should be assessed 
until it is clear the medication is safe and well tolerated. 
If  laboratory studies are stable, blood counts and liver 
enzymes can be reduced to every 3 months. Daily folic 
acid supplementation reduces the risk of  side-effects 
with methotrexate and should routinely be prescribed 
for patients on long-term methotrexate.   Leflunomide 
is increasing used as an oral treatment for RA and may 
be used cautiously in combination with methotrexate or 
other DMARDS. Laboratory monitoring of  leflunomide 
is similar to methotrexate. While methotrexate is relatively 
inexpensive, a prescription for leflunomide in the United 
States is several hundred dollars per month.
The clinical skills necessary to safely and effectively 
treat patients with rheumatoid arthritis require a familiarity 
with the costs and potential side-effects of  each drug. 
However, the rewards are high for both the patient and 
clinician. Control of  pain, preservation of  function, and 
prevention of  damage are possible for nearly all patients 
with RA. 
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